Imagine a child unable to attend school or play with friends due to the throbbing pain of a migraine, a condition often dismissed as just a headache but capable of derailing young lives with symptoms like nausea and sensitivity to light. This debilitating neurological disorder affects roughly one
Imagine a healthcare landscape where life-threatening conditions like cytokine release syndrome (CRS), triggered by immunotherapies or severe infections, can be managed with greater affordability and access. This vision is becoming a reality with the recent FDA approval of Celltrion’s Avtozma IV, a
What if a rare and deadly form of lung cancer, long considered a near-hopeless battle, suddenly had a new weapon in its fight? Picture a patient, grappling with the weight of a diagnosis of HER2-mutant non-small cell lung cancer (NSCLC), now finding a glimmer of possibility with an oral therapy
Imagine a political landscape where access to health care hinges on the drawing of district lines, a scenario unfolding right now as advocacy groups and lawmakers clash over congressional maps in a heated battle for influence. With reproductive rights and health funding under threat from
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent European Commission approval of Cabometyx for advanced
Imagine a world where thousands of Americans, including children, face the grim reality of kidney failure within a decade due to rare, debilitating conditions like C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These diseases, affecting around
